Base de dados : MEDLINE
Pesquisa : C08.618.326 [Categoria DeCS]
Referências encontradas : 17441 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1745 ir para página                         

  1 / 17441 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29253921
[Au] Autor:McNamara RJ; Epsley C; Coren E; McKeough ZJ
[Ad] Endereço:Departments of Physiotherapy and Respiratory Medicine, Prince of Wales Hospital, Barker Street, Randwick, NSW, Australia, 2031.
[Ti] Título:Singing for adults with chronic obstructive pulmonary disease (COPD).
[So] Source:Cochrane Database Syst Rev;12:CD012296, 2017 Dec 19.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Singing is a complex physical activity dependent on the use of the lungs for air supply to regulate airflow and create large lung volumes. In singing, exhalation is active and requires active diaphragm contraction and good posture. Chronic obstructive pulmonary disease (COPD) is a progressive, chronic lung disease characterised by airflow obstruction. Singing is an activity with potential to improve health outcomes in people with COPD. OBJECTIVES: To determine the effect of singing on health-related quality of life and dyspnoea in people with COPD. SEARCH METHODS: We identified trials from the Cochrane Airways Specialised Register, ClinicalTrials.gov, the World Health Organization trials portal and PEDro, from their inception to August 2017. We also reviewed reference lists of all primary studies and review articles for additional references. SELECTION CRITERIA: We included randomised controlled trials in people with stable COPD, in which structured supervised singing training of at least four sessions over four weeks' total duration was performed. The singing could be performed individually or as part of a group (choir) facilitated by a singing leader. Studies were included if they compared: 1) singing versus no intervention (usual care) or another control intervention; or 2) singing plus pulmonary rehabilitation versus pulmonary rehabilitation alone. DATA COLLECTION AND ANALYSIS: Two review authors independently screened and selected trials for inclusion, extracted outcome data and assessed risk of bias. We contacted authors of trials for missing data. We calculated mean differences (MDs) using a random-effects model. We were only able to analyse data for the comparison of singing versus no intervention or a control group. MAIN RESULTS: Three studies (a total of 112 participants) were included. All studies randomised participants to a singing group or a control group. The comparison groups included a film workshop, handcraft work, and no intervention. The frequency of the singing intervention in the studies ranged from 1 to 2 times a week over a 6 to 24 week period. The duration of each singing session was 60 minutes.All studies included participants diagnosed with COPD with a mean age ranging from 67 to 72 years and a mean forced expiratory volume in one second (FEV ) ranging from 37% to 64% of predicted values. The sample size of included studies was small (33 to 43 participants) and overall study quality was low to very low. Blinding of personnel and participants was not possible due to the physical nature of the intervention, and selection and reporting bias was present in two studies.For the primary outcome of health-related quality of life, there was no statistically significant improvement in the St George's Respiratory Questionnaire total score (mean difference (MD) -0.82, 95% confidence interval (CI) -4.67 to 3.02, 2 studies, n = 58, low-quality evidence). However, there was a statistically significant improvement in the SF-36 Physical Component Summary (PCS) score favouring the singing group (MD 12.64, 95% CI 5.50 to 19.77, 2 studies, n = 52, low-quality evidence). Only one study reported results for the other primary outcome of dyspnoea, in which the mean improvement in Baseline Dyspnoea Index (BDI) score favouring the singing group was not statistically significant (MD 0.40, 95% CI -0.65 to 1.45, 1 study, n = 30, very low-quality evidence).No studies examined any long-term outcomes and no adverse events or side effects were reported. AUTHORS' CONCLUSIONS: There is low to very low-quality evidence that singing is safe for people with COPD and improves physical health (as measured by the SF-36 physical component score), but not dyspnoea or respiratory-specific quality of life. The evidence is limited due to the low number of studies and the small sample size of each study. No evidence exists examining the long-term effect of singing for people with COPD. The absence of studies examining singing performed in conjunction with pulmonary rehabilitation precludes the formulation of conclusions about the effects of singing in this context. More randomised controlled trials with larger sample sizes and long-term follow-up, and trials examining the effect of singing in addition to pulmonary rehabilitation, are required to determine the effect of singing on health-related quality of life and dyspnoea in people with COPD.
[Mh] Termos MeSH primário: Doença Pulmonar Obstrutiva Crônica/terapia
Qualidade de Vida
Canto/fisiologia
[Mh] Termos MeSH secundário: Idoso
Dispneia/terapia
Seres Humanos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012296.pub2


  2 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223273
[Au] Autor:van der Veer T; In 't Veen JCCM; den Dekker WK; Miedema J
[Ad] Endereço:Department of Pulmonology, Franciscus Gasthuis & Vlietland, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: t.vanderveer@franciscus.nl.
[Ti] Título:A 79-Year-Old Woman With Dyspnea and Hypoxemia That Worsened in an Upright Position.
[So] Source:Chest;152(6):e139-e142, 2017 12.
[Is] ISSN:1931-3543
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE PRESENTATION: A 79-year-old woman presented to the ED with complaints of gradually worsening exertional dyspnea, dizziness, and chest discomfort. For several weeks she had not been able to perform light household work. The patient's medical history mentioned pulmonary embolism following immobilization (2012), several fractures after trauma, an ischemic cerebral vascular accident (2014), and curative treatment for breast cancer (1995). Her current medication included esomeprazole, clopidogrel, simvastatin, calcium/vitamin D, amitriptyline, and acetaminophen.
[Mh] Termos MeSH primário: Anormalidades Múltiplas
Aneurisma da Aorta Torácica/complicações
Dispneia/etiologia
Forame Oval Patente/complicações
Hipóxia/etiologia
[Mh] Termos MeSH secundário: Idoso
Aneurisma da Aorta Torácica/diagnóstico
Cateterismo Cardíaco
Procedimentos Cirúrgicos Cardíacos/métodos
Diagnóstico Diferencial
Dispneia/diagnóstico
Ecocardiografia
Feminino
Forame Oval Patente/diagnóstico
Forame Oval Patente/cirurgia
Seres Humanos
Hipóxia/diagnóstico
Dispositivo para Oclusão Septal
Síndrome
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  3 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29304074
[Au] Autor:Ekström M; Sundh J; Schiöler L; Lindberg E; Rosengren A; Bergström G; Angerås O; Hedner J; Brandberg J; Bake B; Torén K
[Ad] Endereço:Department of Respiratory Medicine and Allergology, Institution for Clinical Sciences, Lund University, Lund, Sweden.
[Ti] Título:Absolute lung size and the sex difference in breathlessness in the general population.
[So] Source:PLoS One;13(1):e0190876, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Breathlessness is associated with major adverse health outcomes and is twice as common in women as men in the general population. We evaluated whether this is related to their lower absolute lung volumes. METHODS: Cross-sectional analysis of the population-based Swedish CardioPulmonarybioImage Study (SCAPIS) Pilot, including static spirometry and diffusing capacity (n = 1,013; 49% women). Breathlessness was measured using the modified Medical Research Council (mMRC) scale and analyzed using ordinal logistic regression adjusting for age, pack-years of smoking, body mass index, chronic airway limitation, asthma, chronic bronchitis, depression and anxiety in all models. RESULTS: Breathlessness was twice as common in women as in men; adjusted odds ratio (OR) 2.20 (95% confidence interval, 1.32-3.66). Lower absolute lung volumes were associated with increased breathlessness prevalence in both men and women. The sex difference in breathlessness was unchanged when adjusting for lung function in %predicted, but disappeared when controlling for absolute values of total lung capacity (OR 1.12; 0.59-2.15), inspiratory capacity (OR 1.26; 0.68-2.35), forced vital capacity (OR 0.84; 0.42-1.66), forced expiratory volume in one second (OR 0.70; 0.36-1.35) or lung diffusing capacity (OR 1.07; 0.58-1.97). CONCLUSION: In the general population, the markedly higher prevalence of breathlessness in women is related to their smaller absolute lung volumes.
[Mh] Termos MeSH primário: Dispneia/fisiopatologia
Pulmão/anatomia & histologia
Fatores Sexuais
[Mh] Termos MeSH secundário: Estudos Transversais
Feminino
Seres Humanos
Pulmão/fisiopatologia
Masculino
Meia-Idade
Testes de Função Respiratória
Suécia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190876


  4 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29208249
[Au] Autor:Yang KQ; Meng X; Zhang Y; Fan P; Wang LP; Zhang HM; Wu HY; Jiang XJ; Cai J; Zhou XL; Hui RT; Zheng DY; Liu LS
[Ad] Endereço:Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
[Ti] Título:Aortic Aneurysm in Takayasu Arteritis.
[So] Source:Am J Med Sci;354(6):539-547, 2017 12.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Aortic aneurysm (AA) is a severe complication of Takayasu arteritis (TA). This study aimed to evaluate the prevalence, clinical and imaging features, management and long-term outcomes of AA in patients with TA. MATERIALS AND METHODS: A retrospective study was performed of TA patients with AA admitted to Fuwai Hospital from 1996-2015. Baseline clinical data and follow-up data of TA patients with AA were collected and analyzed. RESULTS: Thirty-nine (4.2%) of 934 patients with TA were identified with AA that was related to vasculitis. The mean age at disease onset was 31 ± 10 years, with a female-to-male ratio of 1.79:1. The ascending aorta was the most common site of the aneurysmal lesion (18, 33.3%), and the most frequent manifestations associated with AA were chest tightness (12, 30.8%) and shortness of breath (12, 30.8%), which were usually concomitant with aortic valve insufficiency. Involvement of multiple sites in AA was found in 8 patients (20.5%), and multiple AAs were found in 5 patients (12.8%). No significant difference was observed in clinical and imaging findings between sexes. Of 25 patients (64.1%) with a median 72-month follow-up, 1 patient suffered from heart failure owing to perivalvular leakage, and 1 patient died, possibly related to severe complications of the operation. CONCLUSIONS: The prevalence of AA is relatively low in Chinese patients with TA. AA seems to develop more frequently in male patients with TA. Management should consider location and size of AA, complexity of vessel lesions and disease status. Long-term follow-up is indispensable.
[Mh] Termos MeSH primário: Aneurisma Aórtico/etiologia
Arterite de Takayasu/complicações
[Mh] Termos MeSH secundário: Adulto
Aneurisma Aórtico/diagnóstico
Aneurisma Aórtico/epidemiologia
Aneurisma Aórtico/patologia
Dor no Peito/etiologia
Angiografia por Tomografia Computadorizada
Dispneia/etiologia
Feminino
Seres Humanos
Masculino
Prevalência
Estudos Retrospectivos
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  5 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466536
[Au] Autor:Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
[Ad] Endereço:Dana-Farber Cancer Institute, Boston, MA, USA.
[Ti] Título:A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
[So] Source:Br J Haematol;178(4):547-560, 2017 08.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven clinically relevant primary [congestive heart failure (CHF), arrhythmias, ischaemic heart disease (IHD), cardiac death] and secondary (hypertension, dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 2509 bortezomib-treated patients and 1445 patients in non-bortezomib-based control arms were included. The incidence of grade ≥3 CHF was 1·3-4·0% in studies in relapsed/refractory MM and 1·2-4·7% in previously untreated MM (2·0-7·6% all grades), with no significant differences between bortezomib- and non-bortezomib-based arms in comparative studies. Incidences of arrhythmias (1·3-5·9% grade ≥2; 0·6-4·1% grade ≥3), IHD (1·2-2·9% all grades; 0·4-2·7% grade ≥3) and cardiac death (0-1·4%) were low, with no differences between bortezomib-based and non-bortezomib-based arms. Higher rates of oedema (mostly grade 1/2) were seen in bortezomib-based versus non-bortezomib-based arms in one study and a pooled transplant study analysis. Logistic regression analyses of comparative studies showed no impact on cardiac risk with bortezomib-based versus non-bortezomib-based treatment. Bortezomib-based treatment was associated with low incidences of cardiac events.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Bortezomib/efeitos adversos
Doenças Cardiovasculares/induzido quimicamente
Mieloma Múltiplo/tratamento farmacológico
Inibidores de Proteassoma/efeitos adversos
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Benchmarking
Bortezomib/uso terapêutico
Ensaios Clínicos Fase II como Assunto
Ensaios Clínicos Fase III como Assunto
Dispneia/induzido quimicamente
Insuficiência Cardíaca/induzido quimicamente
Seres Humanos
Inibidores de Proteassoma/uso terapêutico
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Proteasome Inhibitors); 69G8BD63PP (Bortezomib)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14708


  6 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374718
[Au] Autor:Nieder C; Kämpe TA; Engljähringer K
[Ad] Endereço:Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway carsten.nieder@nlsh.no.
[Ti] Título:Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
[So] Source:Anticancer Res;38(2):901-904, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: A considerable proportion of patients with incurable cancer experience dyspnea. This study evaluates associations between the feeling of dyspnea, as quantified by radiotherapy patients scoring their symptoms before palliative treatment with the Edmonton symptom assessment system (ESAS), and potential underlying causes. PATIENTS AND METHODS: Retrospective comparison of the incidence of different parameters that could cause a feeling of dyspnea in two groups, patients with no or minimal dyspnea (ESAS score 0-2) and those with dyspnea scores >2. RESULTS: The mean dyspnea score of all 102 patients was 2.6. Dyspnea scores >2 were present in 68% of patients with lung cancer, 50% of those with breast cancer, 39% of those with prostate cancer and 26% of those with other tumors (p=0.025). Dyspnea scores >2 were also present in 69% of patients with pleural effusion (vs. 40% in patients without pleural effusion), p=0.031. Among patients treated with palliative thoracic radiotherapy, 71% had dyspnea scores >2 (40% if other targets were irradiated), p=0.041. In 13% of patients, anemia and pulmonary comorbidity were the most likely explanation for dyspnea. In 29% the feeling of dyspnea could not be related to objective findings. CONCLUSION: In the majority of patients, the feeling of dyspnea was associated with the presence of thoracic metastases with or without pleural effusion from extrathoracic primary tumors or with a lung cancer diagnosis. A substantial proportion of patients reported dyspnea that could be related neither to cancer burden nor comorbidity.
[Mh] Termos MeSH primário: Dispneia/etiologia
Neoplasias/complicações
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/complicações
Neoplasias da Mama/fisiopatologia
Dispneia/fisiopatologia
Feminino
Seres Humanos
Neoplasias Pulmonares/complicações
Neoplasias Pulmonares/fisiopatologia
Neoplasias Pulmonares/secundário
Masculino
Meia-Idade
Neoplasias/fisiopatologia
Neoplasias da Próstata/complicações
Neoplasias da Próstata/fisiopatologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  7 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464852
[Au] Autor:Al-Haidary AS; Alotaibi W; Alhaider SA; Al-Saleh S
[Ad] Endereço:Department of Pediatrics, King Fahad Medical City, P.O. Box 59046, Riyadh, 11525, Saudi Arabia. adelsanhan@yahoo.com.
[Ti] Título:A newly identified novel variant in the CSF2RA gene in a child with pulmonary alveolar proteinosis: a case report.
[So] Source:J Med Case Rep;11(1):122, 2017 May 02.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The congenital form of pulmonary alveolar proteinosis due to colony stimulating factor 2 receptor alpha gene mutations is a rare disease with only a few cases reported worldwide. In this study we report a new case of pulmonary alveolar proteinosis with a novel variant in colony stimulating factor 2 receptor alpha gene. CASE PRESENTATION: A 5-year-old Saudi boy presented with a history of progressive dyspnea over 6 months; he was diagnosed as having pulmonary alveolar proteinosis. A molecular study revealed a novel variation in colony stimulating factor 2 receptor alpha gene. His clinical condition showed significant improvement after whole lung lavage. CONCLUSIONS: This case has the typical presentation of congenital pulmonary alveolar proteinosis due to colony stimulating factor 2 receptor alpha defect with a novel variant in this gene likely to be pathogenic.
[Mh] Termos MeSH primário: Lavagem Broncoalveolar
Dispneia/fisiopatologia
Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética
Mutação
Proteinose Alveolar Pulmonar/congênito
Receptores de Fator Estimulador das Colônias de Granulócitos e Macrófagos/genética
[Mh] Termos MeSH secundário: Pré-Escolar
Progressão da Doença
Dispneia/etiologia
Dispneia/terapia
Marcadores Genéticos
Fator Estimulador de Colônias de Granulócitos e Macrófagos/fisiologia
Seres Humanos
Masculino
Linhagem
Proteinose Alveolar Pulmonar/genética
Proteinose Alveolar Pulmonar/fisiopatologia
Proteinose Alveolar Pulmonar/terapia
Irmãos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CSF2RA protein, human); 0 (Genetic Markers); 0 (Receptors, Granulocyte-Macrophage Colony-Stimulating Factor); 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1285-4


  8 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455405
[Au] Autor:Li Kam Wa ME; Taraborrelli P; Hayat S; Lim PB
[Ad] Endereço:Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK.
[Ti] Título:Respiration driven excessive sinus tachycardia treated with clonidine.
[So] Source:BMJ Case Rep;2017, 2017 Apr 28.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A 26-year-old man presented to our syncope service with debilitating daily palpitations, shortness of breath, presyncope and syncope following a severe viral respiratory illness 4 years previously. Mobitz type II block had previously been identified, leading to a permanent pacemaker and no further episodes of frank syncope. Transthoracic echocardiography, electophysiological study and repeated urine metanepherines were normal. His palpitations and presyncope were reproducible on deep inspiration, coughing, isometric hand exercise and passive leg raises. We demonstrated rapid increases in heart rate with no change in morphology on his 12 lead ECG. His symptoms were resistant to fludrocortisone, flecainide, ß blockers and ivabradine. Initiation of clonidine in combination with ivabradine led to rapid resolution of his symptoms. We suggest that an excessive respiratory sinus arrhythmia was responsible for his symptoms and achieved an excellent response with the centrally acting sympatholytic clonidine, where previous peripherally acting treatments had failed.
[Mh] Termos MeSH primário: Inalação/fisiologia
Síncope/fisiopatologia
Taquicardia Sinusal/complicações
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem
Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico
Adulto
Benzazepinas/administração & dosagem
Benzazepinas/uso terapêutico
Fármacos Cardiovasculares/administração & dosagem
Fármacos Cardiovasculares/uso terapêutico
Clonidina/administração & dosagem
Clonidina/uso terapêutico
Tosse/complicações
Tosse/etiologia
Quimioterapia Combinada/métodos
Dispneia/diagnóstico
Dispneia/etiologia
Ecocardiografia/métodos
Eletrocardiografia/métodos
Seres Humanos
Masculino
Síncope/etiologia
Taquicardia/etiologia
Taquicardia/fisiopatologia
Taquicardia Sinusal/diagnóstico por imagem
Taquicardia Sinusal/tratamento farmacológico
Taquicardia Sinusal/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-2 Receptor Agonists); 0 (Benzazepines); 0 (Cardiovascular Agents); 3H48L0LPZQ (ivabradine); MN3L5RMN02 (Clonidine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  9 / 17441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365382
[Au] Autor:Chen QP; Zhou RF; Zhang YM; Yang L
[Ad] Endereço:Department of Paediatrics, Taizhou People's Hospital, Taizhou 225300, China.
[Ti] Título:[Efficacy of systemic glucocorticoids combined with inhaled steroid on children with acute laryngitis].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):53-56, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the efficacy of systemic glucocorticoid (steroid) combined with high dose inhaled steroid in the treatment of children with acute laryngitis. A total of 78 children with acute laryngitis were randomly divided into study group( =40) and control group( =38) between November 2016 and April 2017. In addition to routine treatment of anti infection and symptomatic treatment, Dexamethasone injection(0.3-0.5 mg/kg, 1-3 d, according to the patient's condition) was provided to each group. In addition to the treatment mentioned above, the study group were assigned to receive 1.0 mg Budesonide suspension for inhalation, oxygen-driven atomizing inhalation, every/30 minutes, 2 times in a row, after that every 12 hours. The improvement of inspiratory dyspnea, hoarseness, barking cough and wheezing of both groups was evaluated at 30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 72 h after treatment.Sigmaplot 11.5 software was used to analyze the data. No significant difference was detected in terms of inspiratory dyspnea, hoarseness, barking cough or stridor score before treatment between the two groups( >0.05). Compared with those before treatment, symptoms of inspiratory dyspnea, hoarseness, barking cough and stridor score of both groups improved markedly at 12 h and 24 h after treatment( <0.05). While there was no significant difference regarding inspiratory dyspnea, hoarseness, barking cough or stridor score at each time point after treatment between the two groups( >0.05). The effective rate was 92.50% and 92.11% in study group and control group, respectively, and no significant difference was noted ( >0.05). Compared with single systemic glucocorticoid, systemic glucocorticoids combined with inhaled steroid possessed similar efficacy in treating acute laryngitis and relieving laryngeal obstruction of children.
[Mh] Termos MeSH primário: Budesonida/uso terapêutico
Dexametasona/uso terapêutico
Glucocorticoides/uso terapêutico
Laringite/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Administração por Inalação
Budesonida/administração & dosagem
Criança
Tosse/tratamento farmacológico
Dexametasona/administração & dosagem
Esquema de Medicação
Dispneia/tratamento farmacológico
Glucocorticoides/administração & dosagem
Rouquidão/tratamento farmacológico
Seres Humanos
Nebulizadores e Vaporizadores
Sons Respiratórios/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucocorticoids); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.012


  10 / 17441 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328561
[Au] Autor:Ristic-Andelkov A; Mladenovic Z; Baskot B; Babic S; Ristic M; Misic T; Ratkovic N; Vukotic S; Torbica L; Vranes D; Grdinic A; Pandrc M
[Ti] Título:Lung ultrasound for severe acute dyspnea evaluation in critical care patients.
[So] Source:Vojnosanit Pregl;73(10):950-5, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Mh] Termos MeSH primário: Cuidados Críticos/métodos
Dispneia/diagnóstico por imagem
Insuficiência Cardíaca/diagnóstico por imagem
Pneumopatias/diagnóstico por imagem
Pulmão/diagnóstico por imagem
Ultrassonografia
[Mh] Termos MeSH secundário: Doença Aguda
Estado Terminal
Diagnóstico Diferencial
Dispneia/etiologia
Dispneia/fisiopatologia
Insuficiência Cardíaca/complicações
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Pulmão/fisiopatologia
Pneumopatias/complicações
Pneumopatias/fisiopatologia
Valor Preditivo dos Testes
Prognóstico
Fatores de Risco
Índice de Gravidade de Doença
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150609085R



página 1 de 1745 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde